Table 1 Demographic and clinico-pathological characteristics of endometrial cancer subjects from institutional and national endometrial cancer database
Institutional database | National database | |||||||
|---|---|---|---|---|---|---|---|---|
LVSI absent (N = 227) | LVSI present (N = 48) | Total (N = 275) | p value | LVSI absent (N = 24,035) n (%) | LVSI present (N = 3766) n (%) | Total (N = 27,801) n (%) | p value | |
Age mean (SD) (n = 275) | 63.2 (10.5) | 64.8 (9.8) | 63.5 (10.3) | 0.3 | 61.6 (10.5) | 64.1 (9.8) | 61.9 (10.4) | < 0.001 |
Race (n = 274) | 0.3 | 0.35 | ||||||
White | 179 (79.2%) | 32 (66.7%) | 211 (77.0%) | 21,201 (88.2) | 3336 (88.5) | 24,537 (88.3) | ||
African American | 38 (16.8%) | 10 (20.8%) | 48 (17.5%) | 1551 (6.4) | 228 (6.1) | 1779 (6.4) | ||
Asian | 2 (0.9%) | 1 (2.1%) | 3 (1.1%) | 534 (2.2) | 102 (2.7) | 636 (2.3) | ||
Native American, Alaskan Native | 1 (0.4%) | 1 (2.1%) | 2 (0.7%) | – | – | – | ||
Native Hawaiian, Pacific Islander | 1 (0.4%) | 1 (2.1%) | 2 (0.7%) | – | – | – | ||
Other | 3 (1.4%) | 1 (2.1%) | 4 (1.5%) | 496 (2.1) | 71 (1.9) | 567 (2.0) | ||
Unknown | 2 (0.9%) | 2 (4.1%) | 4 (1.5%) | 253 (1.1) | 29 (0.8) | 282 (1.0) | ||
Stage (n = 269) | 0.047 | < 0.001 | ||||||
Ia | 84 (38.0%) | 11 (22.9%) | 95 (35.3%) | 18,713 (77.9) | 1651(43.8) | 20,364 (73.2) | ||
Ib | 137 (62.0%) | 37 (77.1%) | 174 (64.7%) | 5322 (22.1) | 2115 (56.2) | 7437 (26.8) | ||
Grade (n = 275) | < 0.001* | < 0.001* | ||||||
1 | 120 (52.9%) | 8 (16.7%) | 128 (46.5%) | 10,832 (45.1) | 873 (23.1) | 11,705 (42.1) | ||
2 | 77 (33.9%) | 22 (45.8%) | 99 (36.0%) | 7165 (29.8) | 1282 (34.2) | 8447 (30.4) | ||
3 | 30 (13.2%) | 18 (37.5%) | 48 (17.5%) | 2552 (10.6) | 1070 (28.5) | 3622 (13.1) | ||
Unknown | – | – | – | 3486 (14.5) | 541 (14.2) | 4027 (14.4) | ||
Depth of invasion (n = 275) | < 0.001 | |||||||
Inner 1/3 | 146 (64.3%) | 16 (33.3%) | 162 (58.9%) | – | – | – | ||
Middle 1/3 | 59 (26.0%) | 17 (35.4%) | 76 (27.6%) | – | – | – | ||
Outer 1/3 | 22 (9.7%) | 15 (31.3%) | 37 (13.5%) | – | – | – | ||
High-intermediate risk (n = 275) | < 0.001 | < 0.001 | ||||||
No | 178 (78.4%) | 9 (18.7%) | 187 (68%) | 12,631 (52.8) | 657 (17.5) | 13,288 (48.0) | ||
Yes | 49 (21.6%) | 39 (81.3%) | 88 (32%) | 11,404 (47.2) | 3109 (82.5) | 14,513 (52.0) | ||
Adjuvant therapy (n = 63) | 0.15** | < 0.001** | ||||||
External beam radiation therapy | 2 (0.9%) | 8 (16.7%) | 10 (3.6%) | 394 (1.6) | 349 (9.4) | 743 (2.7) | ||
Vaginal brachytherapy | 16 (7.1%) | 14 (29.2%) | 30 (10.9%) | 3788 (15.7) | 1520 (40.3) | 5308 (19.0) | ||
Hormonal | 8 (3.9%) | 5 (14.7%) | 13 (5.4%) | 115 (0.5) | 16 (0.4) | 131 (0.5) | ||
Chemotherapy | 3 (1.5%) | 6 (17.1%) | 9 (3.8%) | 915 (3.8) | 520 (13.8) | 1435 (5.2) | ||
Other | 1 (0.4%) | 0 (0%) | 1 (0.4%) | 1 (0.004) | 2 (0.1) | 3 (0.01) | ||
No additional treatment | – | – | – | 18,822 (78.4) | 1359 (36.0) | 20,181 (72.6) | ||